F757 in Alaska. Pick another state for the same tag.
Against expectation — 2025
Alaska cites F757 less often than its own record predicts
Versus expected share0.67×
0.67 times the national share — cited less often here than elsewhere.
Share of Alaska citations0.53%
Of every deficiency written in Alaska in 2025, this is the portion that was F757.
Alaska0.53%
National0.80%
Share of all citations that were F757.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What Alaska surveyors wrote
F757 findings written in Alaska, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
D · No harm, potential for more than minimal, isolatedNovember 21, 2025
. Based on record review and interview, the facility failed to ensure the drug regimen for one resident (#41), out of 12 sampled residents, was free from unnecessary medication. Specifically, the facility failed to prevent duplicate drug therapy by continuing a maintenance dose concurrently with a high-dose of prednisone (corticosteroid medication used to reduce inflammation and suppress the immune system) without a documented clinical rationale confirming the benefits of maintaining both doses of the medication. This failed practice placed Resident #41 at risk for potential adverse effects from unnecessary medication administration related to excessive corticosteroid exposure. …
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction